IL6 and ovarian neoplasm: Thus, the upregulation of the IL6-STAT3-HIF pathway in OCCA may be exploited as a biomarker to clinically differentiate OCCA from other ovarian tumor types [7], and inhibition of the IL-6-STAT3 signaling autocrine pathway may offer yet another molecular targeting strategy in the management of cisplatin- and paclitaxel-resistant ovarian cancers [259, 262].